Hepat Mon. 2018 April; 18(4):e67709. Published online 2018 March 26. doi: 10.5812/hepatmon.67709. Research Article Calculation of Wiener Indices of Thiazolides: The Potent Inhibitors of Hepatitis B Virus and Hepatitis C Virus Replication Mobeen Munir, 1 Shazia Rafique, 2 Amjad Ali, 2 Muhammad Idrees, 2,3 and Shin Min Kang 4,5,* 1 Division of Science and Technology, University of Education Lahore, Pakistan 2 Centre for Applied Molecular Biology, University of the Punjab, Lahore, Pakistan 3 Vice Chancellor Hazara University, Mansehra, Pakistan 4 Department of Mathematics RINS, Gyeongsang National University, Jinju, Korea 5 Center for General Education, China Medical University, Taichung, Taiwan * Corresponding author: Shin Min Kang, Department of Mathematics and RINS, Gyeongsang National University, Jinju 52828, Korea. E-mail: smkang@gnu.ac.kr Received 2016 November 20; Revised 2017 January 15; Accepted 2017 December 20. Abstract Background: Hepatitis C Virus is the leading cause of death in liver-related diseases globally. The identification of innovative drug targets and inexpensive therapeutic agents remain a high priority for chronic HCV infection management. In the last few decades, the availability of highly effective interferon-free regimens for HCV treatment is the only possible option for cure of the large num- ber of chronic HCV patients. Direct acting antiviral drugs, such as Sovaldi, are expensive and their efficacy varies from genotype to genotype. In addition, these drugs are advised in combination with ribavirin and interferon, which makes the treatment costly. Thiazolide derivatives are recently emerging antiviral agents that may change current and future therapies for liver complications caused by HBV and HCV. Nitazoxanides are synthetic nitrothiazolyl-salicylamide derivative of thiazolide, which have been used as anti-HCV drugs. The derivatives of thiazolides were randomly screened for anti-HCV and anti-HBV activity in a biological system, yet the stability and other properties of these compounds were not tested. Representing chemical compounds with Hosoya-polynomial produces closed forms of many topological indices, which correlate with the chemical properties of the material under investiga- tion. These indices are used in the development of quantitative structure-activity relationships (QSARs), in which the biological activity and other properties of molecules like boiling point, stability, strain energy, radius of gyration, and viscosity are correlated with their structures.In this paper, Hosoya-polynomials and Weiner indices of some derivatives of thiazolides were determined. Graphs of Hosoya polynomial for these derivatives were also plotted. Objectives: In this study, therefore, it was attempted to extend the research to check the stability and other properties of thiazolide derivatives using the Hosoya-polynomial and Wiener index. Methods: In the first step, Hosoya polynomials of some famous classes of thiazolides were computed, followed by computation of F Wiener indices of thiazolide derivatives. Distance-based graph invariants were used as a structure-descriptor for predicting various physicochemical properties of organic compounds. The Weiner index of 8 derivatives of thiazolidines was computed, including RM-4832, RM-4848, RM-4850, RM-4851, RM-4852, RM-4850, Tizoxanide, and Nitazoxanide. Results: These indices indicate the physiochemical properties of these compounds in relation to stability in the given biological environment. The Wiener indices of the studied compounds ranged from 374 to 684. Out of 8 analyzed compounds, 3 showed Wiener indices of 374. RM-4863 had a maximum index value of 684. Graphs were also drawn for Hosoya polynomials of all these thiazole derivatives. Conclusions: The results confirmed that RM-4863 is a stable physiochemical compound, which might be used as an effective drug for treating viral infections, including HCV and HBV. Keywords: Wiener Index, Computation, Thiazolide, Anti-HCV, Anti-HBV, Inhibition, Potent, Hosoya Polynomial 1. Background Hepatitis C Virus (HCV) causes chronic infection in more than 50% of the infected individuals and may lead to fatal liver complications (1). More than 200 million peo- ple across the globe are chronically infected with HCV (2). Chronic HCV infection can lead to complex sequela, includ- ing diabetes, steatosis, cirrhosis, and ultimately hepatocel- lular carcinoma (HCC) (3). The primary objective of HCV treatment is to inhibit and consequently eradicate HCV RNA by having sustained virological response (SVR) against the infected virus. Treatment effectiveness is defined by the absence of detectable HCV RNA in the patient serum Copyright © 2018, Hepatitis Monthly. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.